

## **PRESS RELEASE**

### **“The Future Of Healthcare in Africa”**

#### **Report by the Economist Intelligence Unit gives high level picture of the continent’s healthcare challenges**

**Beerse, Belgium, March 1 2012** – By 2022 reformed healthcare systems in African countries could succeed in making quality care available to a majority of their citizens, given the political will to meet healthcare spending targets. This is one of the conclusions in a new report by the Economist Intelligence Unit (EIU), commissioned by Janssen Pharmaceutica NV and called “***The Future Of Healthcare In Africa***”.

The report focuses on five possible future scenarios for African healthcare systems over the next ten years. Thirty four leading healthcare experts, representing the entire chain of stakeholders across the sector, helped the EIU’s expert analysts identify the key trends shaping African healthcare systems and these were then used to develop scenarios that depict the possible health landscape on the continent in 2022 (see Press Release by The Economist for more information).

Jane Griffiths, Company Group Chairman of Janssen in EMEA, explains : “The study draws a very high level picture, combining statistics with trends and possible scenarios that could form the basis for further discussions on which policy options to take. We did the same thing last year with “***The Future Of Healthcare In Europe***”. Solutions can only become clearer by having open and constructive discussions with all parties involved, based on factual analyses”.

Janssen is active in Africa in many ways. Apart from selling its products across the region via its offices in Algeria, Egypt and South Africa, and working with distributors elsewhere, the company has also set up a number of projects specifically designed for infectious and neglected diseases, including research for a new tuberculosis treatment in collaboration with the TB Alliance, a microbicide targeting HIV, with the International Partnership for Microbicides, a new research programme against elephantiasis and river blindness with the Drugs for Neglected Diseases initiative (DNDi) and the Gates Foundation, as well as against sleeping sickness, Chagas and visceral leishmaniasis.

For the products that are already approved, Janssen sets up access programmes, such as the recently concluded agreements with generic manufacturers in Africa to manufacture and distribute the company’s HIV/AIDS compounds, or the free distribution of treatments against

intestinal infections with the Children Without Worms programme (More information is to be found in the attached backgrounder).

Commenting on the various scenarios presented in the report, Jane Griffiths continues “Broad and systematic access to healthcare can only be achieved when the proper healthcare insurance systems are in place, both public and private. This requires an investment by the authorities, but it is one that will offer immediate and sustainable returns to every country’s economy, through decreased mortality, continued education, better stability in the income of households. It is encouraging to see the results that countries such as Ghana, Burkina Faso, Kenya, Burundi, Tunisia and Ethiopia have achieved in the past years. We tend to focus too much on what doesn’t work in Africa, but we can learn only from the good examples”.

With regard to medicines, specific initiatives can be taken which could benefit the region : “Regulatory harmonisation for the approval of medicines should be high on the agenda in Africa, “ says Jane Griffiths. “Some of our HIV medicines have delayed market access because of different requirements across the region. Counterfeiting is also a scourge, and we have started with a pilot project with the Nigerian authorities to check how patients can verify the product’s authenticity through text messaging. Technology options could mean a lot in the continent”.

### **About the report**

The report “The Future Of Healthcare In Africa” can be downloaded as a free pdf document from: <http://www.janssen-emea.com/future-of-healthcare-africa>

The report “The Future Of Healthcare In Europe” can be downloaded as a free pdf document from: <http://www.janssen-emea.com/future-of-healthcare-europe>

### **About Janssen**

The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology, immunology, neuroscience, infectious disease, and cardiovascular and metabolic diseases.

Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world.

More information can be found at [www.janssen-emea.com](http://www.janssen-emea.com)

For further information

Stefan Gijssels, Vice President Communications & Public Affairs : +32 473 710 425 or  
[sgijssel@its.jnj.com](mailto:sgijssel@its.jnj.com)

## **BACKGROUNDER**

### **JANSSEN'S MAIN ACTIVITIES IN AFRICA**

#### **Presence**

Janssen has offices in Johannesburg (South Africa), Cairo (Egypt), Algiers (Algeria) and is active around the continent. For example, in Nigeria and Ghana, Janssen works through locally appointed partners for the distribution of products in disease areas like infections by worms and other organisms, gastro-intestinal disorders, antifungal treatments, schizophrenia and anemia associated with chronic renal failure. Janssen also has activities in some of these disease areas in countries such as Sierra Leone, Democratic Republic of Congo, Rwanda and Burundi.

In South Africa Janssen supplies nearly 50 originally-researched products to both the private and public sectors, covering a range of therapeutic areas including infectious disease, immunology, oncology, pain management and mental health. In addition, product is also supplied to more than 10 other Southern and East African markets.

#### **Research programmes**

##### HIV/AIDS

Through R&D partnerships, Janssen works to prevent the spread of HIV and reduce the burden of AIDS on women and their families. Microbicides are an innovative HIV prevention tool in the form of gels, films, sponges and other products, applied topically (vaginally) to help prevent sexual transmission of HIV. The Company has led the way in new microbicides R&D, forming the first ever public-private collaboration in the microbicides field in 2004, with the International Partnership for Microbicides (IPM). The Program provided IPM with a royalty-free license for TMC120 (*dapivirine*) to develop, manufacture and distribute the compound as a vaginal microbicide in resourcepoor countries.

##### Tuberculosis

Janssen are currently developing TMC207 (*bedaquiline*), an investigational therapy for the treatment of multi-drug-resistant TB (MDR-TB) that has the potential to address some of the

greatest unmet needs in the field of TB. Today, treatment of MDR-TB requires up to six second line drugs for up to two years, which poses a severe burden on patients and health systems.

### Neglected diseases

Janssen will work with its partners and the Gates Foundation on pre-clinical research and clinical development of a potential new treatment against parasites that cause lymphatic filariasis (elephantiasis) and onchocerciasis (river blindness), two debilitating diseases for which current treatments do not eradicate the parasites. Elephantiasis and river blindness are among the most difficult to treat tropical diseases and afflict hundreds of millions around the world in Southeast Asia, sub-Saharan Africa, Central and South America and other tropical countries. The company is entering into innovative licensing agreements with the Drugs for Neglected Diseases initiative (DNDi) to share compounds and knowledge to generate new drugs for river blindness, lymphatic filariasis, sleeping sickness, Chagas and visceral leishmaniasis.

### Vaccines

Crucell, the vaccines center of Janssen, has research & development for vaccines in tuberculosis, malaria, Ebola and Marburg, HIV and more, all important medical needs in Africa.

### Access programmes

HIV/AIDS - Since 2007, we have proactively and voluntarily entered into licensing agreements with generic manufacturers to ensure sustainable access to, and supply of, our HIV medicines in areas of high

HIV burden and economic vulnerability. These agreements cover 65 countries — together, home to 77% of people living with HIV worldwide. We are working to potentially expand the reach of these agreements to include additional countries.

### Vaccines

Since 2006, over 270 million doses of a pentavalent (DTP-HepB-Hib) paediatric vaccine have been delivered to developing countries, saving many children from disease or worse. Most were low-income countries supplied through Unicef and the Pan American Health Organisation (PAHO). Crucell has become a major partner in protecting children in under-resourced countries. In its commitment to Global Health, Crucell also closely collaborates with the Global Alliance for Vaccines & Immunisation (GAVI Alliance).

### Deworming programmes

In addition, through Children Without Worms , Janssen will extend its donation of a de-worming medication, to treat children with intestinal worms. This medication was also developed by Janssen. Since starting Children Without Worms, a partnership between Johnson & Johnson and The Task Force

for Global Health that supports global efforts to reduce the burden of parasitic infections in children, the company has donated more than 150 million doses of de-worming medication. In 2010, as part of the Millennium Development Goals commitment, the company quadrupled the donation of the medication, committing to provide 200 million doses a year for intestinal worms in 30-40 countries through 2015. Today, it is extending this commitment through 2020.

### Special projects: consumer protection

Janssen is investing in a major anti-counterfeiting campaign for medicines, which is a considerable safety problem in Africa. In Nigeria Janssen has partnered with Sproxil Inc. to deliver Nigerian patients a text message based technology against counterfeit medicines. Pharmaceutical products will be marked by scratch-off labels. The consumer will scratch the label to find a 12 digit number, send the number (free of charge) to a standard phone number and obtains an instant return SMS indicating whether the product is genuine or fake.